Preparation and Statistical Modeling of Solid Lipid Nanoparticles of Dimethyl Fumarate for Better Management of Multiple Sclerosis

Ojha, Smriti; Kumar, Babita

doi:10.15171/apb.2018.027

Cited by 26 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Better entrapment effi ciency with a good drug load confi rms a good drug carrying capacity of nanoformulation, which is one of most desirable characteristics of CS-DS nanoparticles. TEM microphotograph (fi g. 1) also confi rmed that the particles are smooth and spherical with nonaggregation [41] . Zeta potential value predicts the kinetic stability of colloidal dispersions, which is an indication of balance between attractive and repulsive forces of suspended particles.…”

Section: Resultsmentioning

confidence: 82%

“…Cuprizone is a copper chelator and this agent was used to induce toxic demyelination in rodents [41] . The motor behavioural scores, grasping ability and forelimb strength were found to be signifi cantly higher in cuprizone model of Wistar rats after treatment with DMF-loaded CS-DS nanoformulations (Table 3).…”

Section: Table 1: Formulation and Characterisation Of Various Batchesmentioning

confidence: 99%

See 1 more Smart Citation

Neuroprotective Potential of Dimethyl Fumarate-loaded Polymeric Nanoparticles against Multiple Sclerosis

Ojha¹,

Kumar²,

Chadha³

2019

pharmaceutical-sciences

Self Cite

View full text Add to dashboard Cite

Ojha et al.: Development of Dimethyl Fumarate-loaded Chitosan Nanoparticles The aim of the present study was to access the potential of dimethyl fumarate-loaded chitosan polymeric nanoparticles for the management of multiple sclerosis. Dimethyl fumarate-loaded chitosan nanoparticles were prepared by polyelectrolyte complex coaservation technique. The prepared nanoparticles were characterized and found to have an average particle size of 324 nm, zeta potential of-34.85 mV and a poly dispersity index of 0.367. The entrapment effi ciency was found to be 65.36 % and the drug loading was 28 %. The formulation's in vitro drug release profi le and stability parameters were also evaluated. Cumulative percent drug release was found to be 84 % up to 24 hours and the formulation was found to be stable at 28° for 90 days. In vitro neuroprotective effect of the nanoformulation was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay on human neuroblast SH-SY5Y cells and the treated cells showed improved cell viability under hydrogen peroxide-induced cell apoptosis. In vivo cuprizone model for multiple sclerosis in rodents also confi rmed these fi ndings by showing a signifi cant increase in locomotion score.

show abstract

Section: Resultsmentioning

confidence: 82%

Section: Table 1: Formulation and Characterisation Of Various Batchesmentioning

confidence: 99%

Neuroprotective Potential of Dimethyl Fumarate-loaded Polymeric Nanoparticles against Multiple Sclerosis

Ojha¹,

Kumar²,

Chadha³

2019

pharmaceutical-sciences

Self Cite

View full text Add to dashboard Cite

show abstract

“…The negative value of zeta potential could reveal the presence of fatty acid in outer structure of SLN. 45 …”

Section: Resultsmentioning

confidence: 99%

Preparation, Statistical Optimization and Characterization of Propolis-Loaded Solid Lipid Nanoparticles Using Box-Behnken Design

et al. 2020

View full text Add to dashboard Cite

Purpose: Propolis is a resinous material obtained by honeybees with many biological and pharmacological properties which can be used for treatment of various diseases. Current study aims to formulate and characterize propolis-loaded solid lipid nanoparticles (SLNs) carrier system. Methods: The prepared SLNs, composed of glyceryl monostearate (GMS), Soy lecithin, Tween 80 and polyethylene glycol 400 (PEG 400), were fabricated employing solvent emulsification-evaporation technique. In addition, the impact of several variables including concentration ratios of GMS/Soy lecithin and PEG 400/Tween 80 along with emulsification time were evaluated on the size, polydispersity index (PDI) and zeta potential of particles. SLN formulations were optimized using Box-Behnken design. The particles were freeze dried and morphologically studied by scanning electron microscopy (SEM). The in-vitro release profile of propolis entrapped in the optimized nanoparticles was investigated. Results: The mean particle size, PDI, zeta potential, entrapment efficiency (EE) and loading efficiency (LE) of optimized propolis-loaded SLNs were found to be 122.6±22.36 nm, 0.28±0.06, -26.18±3.3 mV, 73.57±0.86% and 3.29±0.27%, respectively. SEM images exhibited nanoparticles to be non-aggregated and in spherical shape. The in-vitro release study showed prolonged release of propolis from nanoparticles. Conclusion: The results implied that the proposed way of SLN preparation could be considered as a proper method for production of propolis loaded colloidal carrier system.

show abstract

“…The main features of the disease reported to occur in early patients include cortical demyelination and meningeal inflammation ( Bø et al, 2003 ; Lucchinetti et al, 2011 ). Recent studies demonstrate that SL NPs and CS NPs can potentially increase the bioavailability and neuroprotective effects of a relapsing-MS drug dimethyl fumarate in rat model ( Ojha and Kumar, 2018 ; Ojha et al, 2019 ). Another study also suggests that glucocorticoids and inorganic–organic hybrid NPs can also be used to treat MS ( Montes-Cobos et al, 2017 ).…”

Section: Nanotechnology In Brain Diseases and Disordersmentioning

confidence: 99%

The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

Ngowi

Wang

Qian

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Brain is by far the most complex organ in the body. It is involved in the regulation of cognitive, behavioral, and emotional activities. The organ is also a target for many diseases and disorders ranging from injuries to cancers and neurodegenerative diseases. Brain diseases are the main causes of disability and one of the leading causes of deaths. Several drugs that have shown potential in improving brain structure and functioning in animal models face many challenges including the delivery, specificity, and toxicity. For many years, researchers have been facing challenge of developing drugs that can cross the physical (blood–brain barrier), electrical, and chemical barriers of the brain and target the desired region with few adverse events. In recent years, nanotechnology emerged as an important technique for modifying and manipulating different objects at the molecular level to obtain desired features. The technique has proven to be useful in diagnosis as well as treatments of brain diseases and disorders by facilitating the delivery of drugs and improving their efficacy. As the subject is still hot, and new research findings are emerging, it is clear that nanotechnology could upgrade health care systems by providing easy and highly efficient diagnostic and treatment methods. In this review, we will focus on the application of nanotechnology in the diagnosis and treatment of brain diseases and disorders by illuminating the potential of nanoparticles.

show abstract

Preparation and Statistical Modeling of Solid Lipid Nanoparticles of Dimethyl Fumarate for Better Management of Multiple Sclerosis

Cited by 26 publications

References 39 publications

Neuroprotective Potential of Dimethyl Fumarate-loaded Polymeric Nanoparticles against Multiple Sclerosis

Neuroprotective Potential of Dimethyl Fumarate-loaded Polymeric Nanoparticles against Multiple Sclerosis

Preparation, Statistical Optimization and Characterization of Propolis-Loaded Solid Lipid Nanoparticles Using Box-Behnken Design

The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

Contact Info

Product

Resources

About